Bausch Pharma

Semaglutide

Purity: >99%

Select vial size:

$112.49$149.99per vial

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native human GLP-1. It has been one of the most extensively studied peptides in metabolic research over the past decade. For laboratory research use only.

Inventory20 in stock

In Stock — Ships within 24-48 hours

USPS Priority ($15) or Express ($25) shipping

For laboratory and research use only

Name: Semaglutide
Dosage / Size: 20mg
Purity: >99% (HPLC Verified)
Category: GLP-1 Agonists
Form: Lyophilized powder
Intended Use: Laboratory & scientific research only

Research Studies & Clinical Trials

SUSTAIN Program (Injectable)

SUSTAIN-1 through SUSTAIN-10 A comprehensive Phase 3 clinical trial program evaluating semaglutide across multiple research settings. Key publications in NEJM, The Lancet, and Diabetes Care (2017-2021).

SUSTAIN-6 (NCT01720446) Cardiovascular outcomes trial published in NEJM (2016). Demonstrated 26% reduction in major adverse cardiovascular events (MACE).

PIONEER Program (Oral)

PIONEER-1 through PIONEER-10 Evaluated oral semaglutide formulation. Published across major journals (2019-2022).

STEP Program

STEP-1 (NCT03548935) Phase 3 study published in NEJM (2021). 68-week study demonstrating significant body weight reduction at 2.4mg weekly dose.

STEP-2 (NCT03552757) Evaluated semaglutide 2.4mg in subjects with type 2 diabetes. Published in The Lancet (2021).

STEP-3 (NCT03611582) Combined semaglutide with intensive behavioral therapy. Published in JAMA (2021).

SELECT Trial (NCT03574597)

Landmark cardiovascular outcomes trial with over 17,600 participants. Published in NEJM (2023). Demonstrated 20% reduction in MACE events.

Mechanism of Action

Semaglutide mimics endogenous GLP-1 with modifications at positions 8 and 34 plus a C-18 fatty acid chain for albumin binding, extending half-life to approximately 7 days.